疏血通注射液治疗缺血性脑血管病的临床研究

选择缺血性脑梗塞急性期痰瘀阻络证患者为临床观察对象,以疏血通注射液为治疗组,血塞通注射液为对照组,分别观察其临床疗效及治疗前后中风病临床症状积分、血瘀证证候学积分改变.结果:治疗组和对照组均有显著疗效,治疗组显效率为38.46%、总有效率为88.46%,对照组显效率为33.33%、总有效率为91.67%,两组疗效相当(P>0.05).治疗组中风病临床症状积分治疗后较治疗前有显著降低(P<0.01),治疗组血瘀证证候学积分治疗后较治疗前有明显改善(P<0.01).结论:疏血通注射液可明显改善缺血性脑血管病急性期患者的临床症状及血瘀证证候状态,有显著的活血化瘀作用.

Clinical Trial of Shuxuetong Injection for the Treatment of Ischemic Cerebrovascular Disease

Patients of acute ischemic cerebral infarction of the collateral phlegm and blood stagnation type were divided into the Shuxuetong Injection (SI) treating group and the Xuesaitong Injection (XI) control group, and the changes in the scores for clinical symptoms of apoplexy and clinical symptoms of blood stagnation syndrome were observed before and after the treatment in the patients. The results showed that both SI and XI were effective in the treatment, the effectual rate was 38 46% and the total effective rate was 88 46% in the SI treating group while the effectual rate was 33 33% and the total effective rate was 91 67% in the XI control group, and there was no significant difference between the rates in the two groups ( P >0 05); and after the treatment in the SI treating group, the score for clinical symptoms of apoplexy was decreased significantly as compared with that before the treatment ( P <0 01), and the score for clinical symptoms of blood stagnation syndrome was also significantly improved as compared with that before the treatment ( P <0 01). The results suggest that SI is very effective in treating the patients of acute ischemic cerebrovascular disease and can markedly relieve the clinical symptoms of apoplexy and the symptomatic state of blood stagnation syndrome by exerting its remarkable effects for activating blood circulation and resolving blood stasis.